Azathioprine dose reduction in inflammatory bowel disease patients on combination therapy: an open‐label, prospective and randomised clinical trial
Alimentary Pharmacology & Therapeutics2017Vol. 46(2), pp. 142–149
Citations Over TimeTop 1% of 2017 papers
Xavier Roblin, Gilles Boschetti, Nicolas Williet, Stéphane Nancey, Hubert Marotte, Anne‐Emmanuelle Berger, Jean–Marc Phelip, Laurent Peyrin‐Biroulet, Jean‐Frédéric Colombel, Émilie Del Tedesco, Stéphane Paul, Bernard Flourié
Abstract
Under combination therapy, AZA dose reduction, but not withdrawal, appears to be as effective as continuation of AZA at full dose.
Related Papers
- → Infliximab, Azathioprine, or Infliximab + Azathioprine for Treatment of Moderate to Severe Ulcerative Colitis: The UC Success Trial(2011)120 cited
- → The efficacy of azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in patients with Crohn’s disease remains uncertain(2004)55 cited
- → Results of Seton Drainage and Infliximab Infusion for Complex Anal Crohn's Disease(2011)9 cited
- → A New Answer to an Old Question: Azathioprine Withdrawal in Quiescent Crohn's Disease(2009)3 cited
- → Azathioprine-Induced Tremor: A Rare, Dose-Dependent Side Effect of Azathioprine in a Patient With Active Crohn Disease(2020)2 cited